Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (August 28th Preview)
-
FDA approvals – rare inflammatory disease
Roivant’s Priovant Therapeutics won U.S. FDA approval for Lisraya (brepocitinib), a once-daily oral pill targeting JAK1 and TYK2, for adults with dermatomyositis. The clearance marks the first approval tied to Roivant’s hub-and-spoke strategy using a licensed asset from Pfizer and sets up commercialization and label-expansion work for additional immunology indications. Separate coverage emphasized the market positioning: the approval gives Priovant a regulatory foothold in a rare autoimmune space dominated by long-term immunosuppression and sets expectations for further clinical development across multiple rare inflammatory disorders where pathway activity overlaps with JAK1/TYK2 biology.
-
Oncology – ADC development accelerates at FDA
CytomX Therapeutics received FDA fast track designation for varsetatug masetecan (Varseta-M; CX-2051), an EpCAM-directed masked antibody-drug conjugate, for relapsed/refractory metastatic colorectal cancer. The designation followed phase 1 dose-expansion data from CTMX-2051-101, with confirmed objective response rates climbing by dose and disease control rates near 90% across evaluable patients. CytomX also flagged a planned registrational monotherapy study window in 2027. The FDA program leans on the early efficacy signal despite limited patient numbers, while safety highlights included diarrhea with a reported grade 3 incidence tied to an updated prophylactic regimen.
-
Immuno-oncology – checkpoint blockade without key dendritic cells
Researchers at Hokkaido University and collaborators reported that immune checkpoint blockade can still trigger the first wave of tumor rejection even when cDC1 dendritic cells are absent. Their results suggest initial effector responses can arise through alternative routes, but checkpoint therapy may fail to establish lasting immune memory without cDC1. The findings directly challenge a widely held assumption that cDC1 presence is required for durable protection following checkpoint blockade, and they clarify where biology may diverge between early tumor clearance and long-term immune surveillance.
-
Oncology – functional genomics maps asciminib resistance
A genetic study mapped broad, convergent resistance mechanisms to asciminib in chronic myeloid leukemia (BCR::ABL1), identifying 279 resistance mutations. The work showed that escape can come from alterations spread across much of the BCR::ABL1 protein, including changes in regulatory regions outside the drug-binding pocket. By building a resistance landscape for asciminib, the analysis gives clinicians and developers a clearer playbook for anticipating failure modes and for designing next-generation inhibitors or combination approaches that target multiple resistance pathways.
-
Platform and pipeline – RNA/DNA sequencing dispute in single-cell tech
A U.S. jury found that Parse Biosciences, a subsidiary of Qiagen, willfully infringed three patents tied to Scale Biosciences technology—acquired by 10x Genomics in 2025—while also upholding patent validity. Damages awarded exceeded $4.8 million based on a royalty model for Parse Evercode whole transcriptome sales from February 2021 through June 30, 2026. The verdict could reshape competitive dynamics in single-cell whole-transcriptome workflows in the U.S., with 10x seeking enhanced damages, attorney’s fees, and a permanent injunction to stop further infringement.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.